CDC logo, Safer Healthier People  CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us






Hydrazine, sulfate (1:1)

RTECS #: MV9625000

CAS #: 10034-93-2


UPDATE: May 2009 MW: 130.14 MF: H4N2•H2O4S


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. SKIN AND EYE IRRITATION DATA:
  3. MUTATION DATA:
  4. TUMORIGENIC DATA:
  5. ACUTE TOXICITY DATA:
  6. OTHER MULTIPLE DOSE DATA:
  7. REVIEWS:
  8. STANDARDS AND REGULATIONS:
  9. NIOSH DOCUMENTATION AND SURVEILLANCE:
  10. STATUS IN FEDERAL AGENCIES:
  11. REFERENCES:

SYNONYMS:

  1. Hydrazine monosulfate
  2. Hydrazine sulfate
  3. Hydrazine sulphate
  4. Hydrazinium sulfate
  1. Hydrazonium sulfate
  2. Idrazina solfato (Italian)
  3. NSC - 150014
  4. Siran hydrazinu (Czech)


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
eye
rabbit
20 mg/24 hour moderate 28ZPAK -,15,1972
skin
human
0.25% CODEDG 15,244,1986


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE
DOSE REFERENCE
cytogenetic analysis hamster ovary 1,167 mg/L PMRSDJ 1,551,1981
DNA adduct oral
hamster
1,035 mg/kg/9 week- intermittent TXAPA9 70,324,1983
DNA damage Bacillus subtilis 200 µg/disc PMRSDJ 1,175,1981
DNA damage rat liver 1 mmol/L EMMUEG 24,181,1994
DNA damage rat liver 3,000 µmol/L/3 hour MUREAV 629,49,2007
DNA inhibition intraperitoneal
mouse
180 mg/kg IJEBA6 19,939,1981
DNA repair Bacillus subtilis 200 µg/disc MUREAV 97,1,1982
DNA repair Escherichia coli 250 µg/disc JJIND8 62,873,1979
DNA repair mouse liver 10 µmol/L JJCREP 79,204,1988
DNA repair Saccharomyes cerevisiae 100 mg/L PMRSDJ 1,502,1981
unscheduled DNA synthesis human fibroblast 1 mg/L PMRSDJ 1,528,1981
host-mediated assay mouse
Salmonella typhimurium
3,100 µg/kg MUREAV 16,189,1972
mutation in microorganisms Escherichia coli 100 µg/plate (+enzymatic activation step) PMRSDJ 1,387,1981
mutation in microorganisms other microorganisms 1,500 µg/L (-enzymatic activation step) MUREAV 173,233,1986
mutation in microorganisms Salmonella typhimurium 5 µg/plate (+/-enzymatic activation step) JJIND8 62,873,1979
mutation in microorganisms Salmonella typhimurium 50 µg/plate (-enzymatic activation step) PMRSDJ 1,351,1981
mutation in microorganisms Saccharomyes cerevisiae 133 mg/L (-enzymatic activation step) PMRSDJ 1,414,1981
mutation in microorganisms Schizosaccharomyces pombe 5 mg/L (+enzymatic activation step) PMRSDJ 1,424,1981
gene conversion and mitotic recombination Saccharomyes cerevisiae 385 ppm PMRSDJ 1,481,1981
morphological transform hamster embryo 1 gm/L AETODY 1,241,1980
morphological transform hamster kidney 2,500 µg/L PMRSDJ 1,638,1981
morphological transform mouse fibroblast 0.1 mg/L/21 day (-enzymatic activation step) EMMUEG 35,300,2000
other mutation test systems Salmonella typhimurium 35 mg/L MUREAV 192,239,1987
sister chromatid exchange hamster lung 100 nmol/L MUREAV 118,103,1983
sex chromosome loss and nondisjunction Saccharomyes cerevisiae 50 mg/L PMRSDJ 1,468,1981


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intraperitoneal
mouse
lowest published toxic dose: 832 mg/kg/8 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
JNCIAM 42,337,1969
intraperitoneal
mouse
toxic dose : 950 mg/kg/10 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
IJCNAW 4,318,1969
intraperitoneal
mouse
toxic dose : 475 mg/kg/5 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
IJCNAW 4,318,1969
oral
hamster
lowest published toxic dose: 29,702 mg/kg/2 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors
CRNGDP 8,439,1987
oral
mouse
lowest published toxic dose: 1,892 mg/kg (multigenerations) Tumorigenic: Carcinogenic by RTECS criteria

Reproductive: Tumorigenic effects: Transplacental tumorigenesis

Lung, Thorax, or Respiration: Tumors
JCROD7 105,258,1983
oral
mouse
lowest published toxic dose: 19 gm/kg/61 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors
JNCIAM 41,331,1968
oral
mouse
toxic dose : 1,664 mg/kg/8 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors
JNCIAM 42,337,1969
oral
mouse
toxic dose : 1,280 mg/kg/4w- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors
BJCAAI 18,543,1964
oral
mouse
toxic dose : 11 gm/kg/46 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
NATUAS 194,488,1962
oral
mouse
toxic dose : 14,080 mg/kg/64 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors
CALEDQ 17,75,1982
oral
mouse
toxic dose : 18,524 mg/kg/84 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors
JCROD7 105,258,1983
oral
mouse
toxic dose : 18,480 mg/kg/84 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors
JCROD7 105,258,1983
oral
mouse
toxic dose : 226 mg/kg Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors
TUMOAB 72,125,1986
oral
rat
lowest published toxic dose: 43 gm/kg/85 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors
JNCIAM 41,331,1968
oral
rat
toxic dose : 38 gm/kg/68 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Liver: Tumors
JNCIAM 41,331,1968


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
inhalation
mammal (species unspecified)
lethal concentration : >6,400 µg/m3 N/R GTPZAB 28(12),56,1984
intraperitoneal
mouse
lethal dose (50 percent kill): 152 mg/kg Liver: Hepatitis (hepatocellular necrosis), diffuse

Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis)
AEHLAU 17,315,1968
intraperitoneal
rat
lethal dose (50 percent kill): 230 mg/kg N/R RPTOAN 41,74,1978
oral
dog
lowest published lethal dose: 100 mg/kg N/R HBAMAK 4,1289,1935
oral
human
lowest published toxic dose: 201 mg/kg/8 day Peripheral Nerve and Sensation: Paresthesia

Behavioral: Somnolence (general depressed activity)

Gastrointestinal: Nausea or vomiting
CCROBU 59,1151,1975
oral
mouse
lethal dose (50 percent kill): 434 mg/kg N/R GTPZAB 28(12),56,1984
oral
rat
lethal dose (50 percent kill): 601 mg/kg N/R 28ZPAK -,15,1972
oral
rabbit
lowest published lethal dose: 100 mg/kg N/R HBAMAK 4,1289,1935
parenteral
mouse
lowest published toxic dose: 80 mg/kg Endocrine: Evidence of thyroid hypofunction

Endocrine: Other changes

Blood: Other changes
JEMEAV 173,357,1991
subcutaneous
mouse
lethal dose (50 percent kill): 455 mg/kg N/R ABMGAJ 21,635,1968


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intraperitoneal
rat
lowest published toxic dose: 1,200 mg/kg/30 day- intermittent Endocrine: Changes in thymus weight

Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Changes in ovarian weight
FATOAO 41,203,1978
oral
mouse
lowest published toxic dose: 1,500 mg/kg/15 day- intermittent Nutritional and Gross Metabolic: Weight loss or decreased weight gain FATOAO 41,203,1978
oral
rat
lowest published toxic dose: 1,500 mg/kg/15 day- intermittent Nutritional and Gross Metabolic: Weight loss or decreased weight gain FATOAO 41,203,1978


REVIEWS:

ORGANIZATION STANDARD
REFERENCE

International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 4,127,1974
TOXICOLOGY REVIEW
MUREAV 584,1,2005
TOXICOLOGY REVIEW
MUREAV 654,114,2008
TOXICOLOGY REVIEW
MUREAV 654,114,2008
TOXICOLOGY REVIEW
MUREAV 672,10,2009
TOXICOLOGY REVIEW
MUREAV 672,17,2009


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE

Occupational Exposure Limit - RUSSIA short term exposure limit 0.1 mg/m3, Skin, JUN2003


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE

National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO HYDRAZINES-air Carcinogen ceiling concentration 0.03 ppm/120 minute NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: X4065;
Number of Industries 4;
Total Number of Facilities 223;
Number of Occupations 5;
Total Number of Employees Exposed 945;
Total Number of Female Employees Exposed 259


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE

EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; Cell transform.-SA7/SHE
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; E coli polA without S9
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse; In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Negative: S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Inconclusive: SHE-clonal assay; Mammalian micronucleus
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE

28ZPAK "Sbornik Vysledku Toxixologickeho Vysetreni Latek A Pripravku," Marhold, J.V., Institut Pro Vychovu Vedoucicn Pracovniku Chemickeho Prumyclu Praha, Czechoslovakia, 1972
ABMGAJ Acta Biologica et Medica Germanica. (Berlin, Ger. Dem. Rep.) V.1-41, 1958-82. For publisher information, see BBIADT.
AEHLAU Archives of Environmental Health. (Heldref Pub., 4000 Albemarle St., NW, Washington, DC 20016) V.1- 1960-
AETODY Advances in Modern Environmental Toxicology. (Senate Press, Inc., P.O. Box 252, Princeton Junction, NJ 08550) V.1- 1980-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975-
CCROBU Cancer Chemotherapy Reports, Part 1. (Washington, DC) V.52(6)-59, 1968-75. For publisher information, see CTRRDO.
CODEDG Contact Dermatitis. Environmental and Occupational Dermatitis. (Munksgaard International Pub., c/o Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003) V.1- 1975-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
FATOAO Farmakologiya i Toksikologiya (Moscow). For English translation, see PHTXA6 and RPTOAN. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.2- 1939-
GTPZAB Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-36, 1957-1992. For publisher information, see MTPEEI
HBAMAK "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." (Leipzig, Ger. Dem. Rep.)
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IJEBA6 Indian Journal of Experimental Biology. (Publications & Information Directorate, CSIR, Hillside Rd., New Delhi 110 012, India) V.1- 1963-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
JCROD7 Journal of Cancer Research and Clinical Oncology. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.93- 1979-
JEMEAV Journal of Experimental Medicine. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10021) V.1- 1896-
JJCREP Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
PMRSDJ Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1981-
RPTOAN Russian Pharmacology and Toxicology (English Translation). Translation of FATOAO. (Euromed Pub., 33, Woodlands Rd., Surbiton, Surrey, UK) V.30- 1967-
TUMOAB Tumori. (Casa Editrice Ambrosiana, Via G. Frua 6, 20146 Milan, Italy) V.1- 1911-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-

RTECS Compound Description:
   Tumorigen
   Drug
   Mutagen
   Human Data
   Hormone
   Primary Irritant

Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  RTECS List |  Contact Us